Real-World Laboratory Analysis of Molecular Biomarkers in Multiple Sclerosis Centers in Central-Eastern European Countries Covering 107 Million Inhabitants

Real-World Laboratory Analysis of Molecular Biomarkers in Multiple Sclerosis Centers in Central-Eastern European Countries Covering 107 Million Inhabitants

A multicenter molecular biomarker survey was conducted in Multiple Sclerosis (MS) centers across Central-Eastern European countries, encompassing a population of 107 million. Our aim was to provide a "snapshot" for future studies investigating the use of molecular biomarkers in MS. A self-...

Teljes leírás

Elmentve itt :
Bibliográfiai részletek
Szerzők: Járdánházy Anett
Berger Thomas
Hegen Harald
Hemmer Bernhard
Bartosik-Psujek Halina
Kes Vanja Basic
Berthele Achim
Drulovic Jelena
Habek Mario
Horakova Dana
Ledinek Alenka Horvat
Havrdova Eva Kubala
Magyari Melinda
Rejdak Konrad
Tiu Cristina
Turcani Peter
Bencsik Krisztina
Kincses Zsigmond Tamás
Vécsei László
Dokumentumtípus: Cikk
Megjelent: 2025
Sorozat:INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES 26 No. 17
Tárgyszavak:
Klinikai orvostan
doi:10.3390/ijms26178274

mtmt:36331785
Online Access:http://publicatio.bibl.u-szeged.hu/37720
Leíró adatok
Tartalmi kivonat:A multicenter molecular biomarker survey was conducted in Multiple Sclerosis (MS) centers across Central-Eastern European countries, encompassing a population of 107 million. Our aim was to provide a "snapshot" for future studies investigating the use of molecular biomarkers in MS. A self-report questionnaire was distributed via email to MS centers in seven Central-Eastern European countries (Croatia, Czech Republic, Poland, Romania, Serbia, Slovakia, and Slovenia) and to four reference centers (two in Austria, one in Germany, and one in Denmark), focusing on cerebrospinal fluid (CSF) analysis and molecular biomarkers in MS. Responding centers routinely request CSF oligoclonal band (OCB) testing in suspected MS cases, although no consensus exists on the number of CSF-restricted bands required to define OCB positivity, either within or between countries. More than half of the surveyed centers in the Czech Republic, Slovakia, Slovenia, and the reference centers request kappa free light chain (κFLC) testing in patients with suspected MS. Neurofilament light chain (NfL) is frequently used as a molecular biomarker for MS in Romania, Slovakia, and the reference centers. In summary, besides the use of CSF-specific OCB there is no consensus among the surveyed countries regarding the use of molecular biomarkers in MS.
Terjedelem/Fizikai jellemzők:19
ISSN:1661-6596

Hasonló tételek